The fight against glioblastoma, the deadliest type of brain tumour, could be transformed by a recent discovery from researchers at University College London (UCL). This cancer is notoriously aggressive, with half of patients losing their lives within a year of diagnosis. Now, scientists believe they may have found a way to keep the disease in check, “locking cancer in a harmless state.”
Cracking the Code of Cancer Spread
Glioblastomas spread rapidly through the brain’s white matter, an area filled with nerve connections known as axons. As the tumour grows, it damages these connections, triggering the brain’s natural clean-up system, Wallerian degeneration. Instead of protecting the brain, this process fuels inflammation and inadvertently gives cancer the perfect conditions to spread.
The research team realized that if they could interfere with this natural repair mechanism, they might prevent glioblastoma from turning the brain’s defenses against itself.
The Role of the SARM1 Gene
At the heart of this breakthrough is a gene called SARM1, which regulates the brain’s response to nerve injury. In experiments on mice genetically engineered to develop glioblastoma, researchers found that switching off SARM1 had stunning results:
- Tumours became less aggressive
- The mice lived longer lives
- Normal brain function was largely preserved
In comparison, mice whose SARM1 gene was active developed fast-growing, devastating tumours.
Mr. Ciaran Hill, consultant neurosurgeon at UCL Hospital and co-author of the study, said the findings highlight an “early stage of the disease that we might be able to treat more effectively.” By stepping in before the cancer becomes unmanageable, doctors could potentially “change how tumours behave, locking them in a more benign state.”
Professor Simona Parrinello, senior author of the study, added that blocking this brain damage could not only slow the tumour but also reduce disability for patients.
A Path Toward New Treatments
Perhaps the most promising part? Drugs designed to block SARM1 are already being developed for other neurological conditions, such as motor neurone disease. This opens the door to potentially repurposing existing treatments for glioblastoma, an opportunity that could bring solutions much faster than starting from scratch.
While the research is still at an early stage and has been tested so far only in mice, it lays crucial groundwork. Tanya Hollands from Cancer Research UK described it as an “important step toward treatments that could not only extend life, but also improve its quality.”
Why It Matters
Glioblastoma affects around 3,000 people in the UK and 12,000 in the US every year. Treatment options surgery, chemotherapy, and radiotherapy, have barely changed in 20 years, while the cancer can double in size in just seven weeks. Survival rates remain tragically low, with only 5% of patients living beyond five years.
That’s why discoveries like this bring genuine hope. For the first time in decades, researchers have identified a clear way to disrupt glioblastoma’s deadly cycle.
Looking Forward
Much work remains before patients can benefit directly. More laboratory studies are needed, and clinical trials will take time. But this breakthrough suggests a future where glioblastoma may no longer be an unstoppable force.
Instead, with the right intervention, it could be held in check, transformed from a fast-growing killer into a manageable condition.
For patients and families facing this devastating diagnosis, that’s a ray of hope worth holding onto.
